The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
Abstract
PURPOSE: We review the status of systemic therapy for patients with advanced renal cell carcinoma. MATERIALS AND METHODS: A literature search was performed on MEDLINE and CANCERLIT to identify results of systemic therapy for patients with renal cell carcinoma published from January 1990 through December 1998. Treatment results of chemotherapy agents, immunotherapy, combination programs and adjuvant therapy were reviewed. RESULTS: No chemotherapy agent has produced response rates that justify its use as a single agent. Interferon-alpha and interleukin (IL)-2 demonstrated low response rates ranging from 10% to 20%. The results of 2 randomized trials suggest that treatment with interferon-alpha compared to vinblastine or medroxyprogesterone achieves a small improvement in survival. Response rates in patients treated with low dose IL-2 are similar to those achieved with a high dose bolus schedule but whether the responses are as durable is being addressed in an ongoing randomized trial. A randomized trial of interferon-alpha plus IL-2 compared to monotherapy with either agent showed increased toxicity but no improvement in survival. In 3 randomized trials no survival benefit was associated with adjuvant interferon-alpha therapy following complete resection of locally advanced renal cell carcinoma. CONCLUSIONS: Despite extensive evaluation of many different treatment modalities, metastatic renal cell carcinoma remains highly resistant to systemic therapy. A few patients exhibit complete or partial responses to interferon and/or IL-2 but most do not respond, and there are few long-term survivors. Preclinical research, and clinical evaluation of new agents and treatment programs to identify improved antitumor activity against metastases remain the highest priorities in this refractory disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Motzer, R. J., Bander, N. H., & Nanus, D. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609193351207 · Cited by 2,219
Self-citationSurvival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Self-citationFyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.688 · Cited by 1,391
Negrier, S., Escudier, B., Lasset, C., Douillard, J.-Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381805 · Cited by 967
Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.8.622 · Cited by 639
(1999) · The Lancet · doi:10.1016/s0140-6736(98)03544-2 · Cited by 601
Atkins, M. B., Robertson, M. J., Gordon, M. S., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D. J., Garzone, P. D., et al. (1997) · PubMed · Cited by 583
Resection of metastatic renal cell carcinoma.
Kavolius, J. P., Mastorakos, D. P., Pavlovich, C., Russo, P., Burt, M. E., & Brady, M. S. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2261 · Cited by 559
Self-citationPyrhönen, S., Salminen, E., Ruutu, M., Lehtonen, T., Nurmi, M., Tammela, T., Juusela, H., Rintala, E., Hietanen, P., & Kellokumpu-Lehtinen, P.-L. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2859 · Cited by 441
STAGE SPECIFIC GUIDELINES FOR SURVEILLANCE AFTER RADICAL NEPHRECTOMY FOR LOCAL RENAL CELL CARCINOMA
LEVY, D. A., SLATON, J. W., SWANSON, D. A., & DINNEY, C. P. N. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)63541-9 · Cited by 351
Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.
Elson, P. J., Witte, R. S., & Trump, D. L. (1988) · PubMed · Cited by 340
Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma
Gleave, M. E., Elhilali, M., Fradet, Y., Davis, I., Venner, P., Saad, F., Klotz, L. H., Moore, M. J., Paton, V., Bajamonde, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381804 · Cited by 308
Motzer, R. J., Rakhit, A. K., Schwartz, L. H., Olencki, T. E., Malone, T., Sandstrom, K., Nadeau, R., Parmar, H. R., & Bukowski, R. M. (1998) · PubMed · Cited by 251
Self-citationCYTOTOXIC CHEMOTHERAPY FOR ADVANCED RENAL CELL CARCINOMA
Yagoda, A., Petrylak, D., & Thompson, S. (1993) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)00489-4 · Cited by 207
Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma
Kim, Y., Giuliano, A. R., Hatch, K. D., Schneider, A., Nour, M., Dallal, G. E., Selhub, J., & Mason, J. B. (1994) · Cancer · doi:10.1002/1097-0142(19940801)74:3<916::aid-cncr2820740319>3.0.co;2-z · Cited by 196
Yang, J. C., Topalian, S. L., Parkinson, D., Schwartzentruber, D. J., Weber, J. S., Ettinghausen, S. E., White, D. E., Steinberg, S. M., Cole, D. J., & Kim, H. I. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1572 · Cited by 170
Sleijfer, D. T., Janssen, R. A., Buter, J., de Vries, E. G., Willemse, P. H., & Mulder, N. H. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1119 · Cited by 169
Thiesse, P., Ollivier, L., Di Stefano-Louineau, D., Négrier, S., Savary, J., Pignard, K., Lasset, C., & Escudier, B. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.12.3507 · Cited by 168
Wigginton, J. M., Komschlies, K. L., Back, T. C., Franco, J. L., Brunda, M. J., & Wiltrout, R. H. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.1.38 · Cited by 153
Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma
Stadler, W. M., Kuzel, T. M., Shapiro, C. M., Sosman, J. A., Clark, J. I., & Vogelzang, N. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2541 · Cited by 123
Principles and Practice of Genitourinary Oncology
Lange, P. H., Leibel, S. A., & Scher, H. I. (1997) · Cited by 117
Motzer, R. J., Nanus, D. M., Russo, P., & Berg, W. J. (1997) · Current Problems in Cancer · doi:10.1016/s0147-0272(97)80007-4 · Cited by 113
Self-citationNeidhart, J. A., Anderson, S. A., Harris, J. E., Rinehart, J. J., László, J., Dexeus, F. H., Einhorn, L. H., Trump, D. L., Benedetto, P. W., & Tuttle, R. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.5.832 · Cited by 103
Joffe, J., Banks, R. E., Forbes, M. A., Hallam, S., Jenkins, A., Patel, P. M., Hall, G. D., Velikova, G., Adams, J., Crossley, A., et al. (1996) · British Journal of Urology · doi:10.1046/j.1464-410x.1996.09573.x · Cited by 77
Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
Motzer, R. J., Lyn, P., Fischer, P., LIANES, P., Ngo, R. L., Cordon‐Cardo, C., & O'Brien, J. P. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1958 · Cited by 77
Self-citationSURGERY OF RENAL CELL CARCINOMA
Couillard, D. R., & White, R. D. (1993) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)00485-7 · Cited by 70
Dutcher, J. P., Atkins, M. B., Fisher, R. I., Weiss, G. R., Margolin, K. A., Aronson, F. R., Sosman, J. A., Lotze, M. T., Gordon, M. S., Logan, T. F., et al. (1997) · PubMed · Cited by 67
Gemcitabine: A phase II study in patients with advanced renal cancer
Mulder, P. H. M. D., Weißbach, L., Jakse, G., Osieka, R., & Blatter, J. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050417 · Cited by 64
Phase II Trial of Taxol in Patients with Metastatic Renal Cell Carcinoma
Einzig, A. I., Gorowski, E., Sasloff, J., & Wiernik, P. H. (1991) · Cancer Investigation · doi:10.3109/07357909109044223 · Cited by 54
Motzer, R. J., Nanus, D. M., O’Moore, P. V., Scher, H. I., Bajorin, D. F., Reuter, V. E., Tong, W. P., Iversen, J., Louison, C., & Albino, A. P. (1992) · PubMed · Cited by 50
Self-citationSamuels, B. L., Hollis, D. R., Rosner, G. L., Trump, D. L., Shapiro, C. L., Vogelzang, N. J., & Schilsky, R. L. (1997) · PubMed · Cited by 49
Phase II trial of topotecan in patients with advanced renal cell carcinoma
Law, T. M., Ilson, D. H., & Motzer, R. J. (1994) · Investigational New Drugs · doi:10.1007/bf00874445 · Cited by 42
Self-citationRecombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial
Stouthard, J. M., Goey, H., de Vries, E., de Mulder, P., Groenewegen, A., Pronk, L., Stoter, G., Sauerwein, H. P., Bakker, P. J. M., & Veenhof, C. H. N. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.137 · Cited by 41
Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma
Mickisch, G., Noordzij, M. A., van de Gaast, A., Gebreamlack, P., Köhrmann, K. U., Mogler-Drautz, E., Küpper, H., & Schröder, F. H. (1995) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf02351065 · Cited by 38
A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma
Berg, W. J., Schwartz, L. H., Amsterdam, A., Mazumdar, M., Vlamis, V., Law, T. M., Nanus, D. M., & Motzer, R. J. (1997) · Investigational New Drugs · doi:10.1023/a:1005902022076 · Cited by 32
Self-citationMarshall, M. E., Wolf, M. K., Crawford, E. D., Taylor, S., Blumenstein, B., Flanigan, R., Meyers, F. J., Hynes, H. E., Barlogie, B., & Eisenberger, M. (1993) · Investigational New Drugs · doi:10.1007/bf00874157 · Cited by 24
Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma
Law, T. M., Mencel, P. J., & Motzer, R. J. (1994) · Investigational New Drugs · doi:10.1007/bf00873048 · Cited by 24
Self-citationSchüler, M., Bruntsch, U., Späth‐Schwalbe, E., Schrezenmeier, H., Peschel, C., Färber, L., Burger, K. J., Leissner, J., Huber, C. H., & Aulitzky, W. E. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10089-2 · Cited by 23
Phase II trial of Didemnin B in patients with advanced renal cell carcinoma
Motzer, R. J., Scher, H. I., Bajorin, D. F., Sternberg, C. N., & Bosl, G. J. (1990) · Investigational New Drugs · doi:10.1007/bf00198598 · Cited by 19
Self-citationWitte, R. S., Hsieh, P., Elson, P. J., Oken, M. M., & Trump, D. L. (1996) · Investigational New Drugs · doi:10.1007/bf00180819 · Cited by 19
High-Dose Cimetidine for the Treatment of Metastatic Renal Cell Carcinoma
Inborn, L., Williams, S. D., Nattam, S. R., & Stephens, D. (1992) · American Journal of Clinical Oncology · doi:10.1097/00000421-199204000-00012 · Cited by 18
Pawinski, A., van Oosterom, A. T., de Wit, R., Fosså, S. D., Croles, J. J., Svedberg, A., Lentz, M. A., & Mulder, P. H. M. D. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)89028-4 · Cited by 17
A Phase II Trial of Edatrexate in Patients with Advanced Renal Cell Carcinoma
Dreicer, R., PROPERT, K. J., Kuzel, T. M., Kirkwood, J. M., O'Dwyer, P. J., & Loehrer, P. J. (1997) · American Journal of Clinical Oncology · doi:10.1097/00000421-199706000-00008 · Cited by 17
Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885
Chang, A. Y., Tu, Z. N., Bryan, G. T., Kirkwood, J. M., Oken, M. M., & Trump, D. L. (1994) · Investigational New Drugs · doi:10.1007/bf00874447 · Cited by 16
Trimetrexate in advanced renal cell carcinoma
Witte, R. S., Elson, P. J., Bryan, G. T., & Trump, D. L. (1992) · Investigational New Drugs · doi:10.1007/bf01275483 · Cited by 11
Cited by
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Self-citationMotzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Self-citationRini, B. I., Campbell, S. C., & Escudier, B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60229-4 · Cited by 1,621
Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576
Self-citationSunitinib in Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., Redman, B. G., Margolin, K. A., Merchan, J. R., Wilding, G., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2516 · Cited by 1,230
Self-citation
Metadata
- Authors
- MOTZER, R. J., & RUSSO, P.
- Venue
- Journal of Urology
- Published
- 2000-02
- Volume
- 163
- Issue
- 2
- Pages
- 408-417
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2041881143
- Cited by
- 603
- References
- 46
- FWCI
- 26.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.